New US label data for Novo Nordisk's Victoza
This article was originally published in Scrip
The US FDA has approved changes to the labelling for Novo Nordisk's diabetes drug Victoza (liraglutide) to include data showing that it is more effective than rival product, Merck & Co's DPP-IV inhibitor Januvia (sitagliptin). The new labelling also adds data on Victoza's use in combination with basal insulin for the treatment of adults with type 2 diabetes.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.